期刊文献+

新骨架小分子南强菌素对紫杉醇耐药性的逆转作用及其机制

Effect and mechanism of deacetyl-mycoepoxydiene on reversing resistance to taxol in tumor cells
原文传递
导出
摘要 目的研究南强菌素(DM)对肿瘤细胞紫杉醇耐药性的逆转作用并探讨其逆转机制。方法 MTT法检测南强菌素对A549/T耐药细胞与A549敏感细胞的毒性及其对紫杉醇敏感性的影响,以Annexin V法检测细胞凋亡率和Rh123在耐药细胞中的积累,HPLC测定细胞内紫杉醇的蓄积量,Western blotting检测Ⅲ型β微管蛋白的表达水平。结果南强菌素可显著提高A549/T细胞对紫杉醇的敏感性,增加紫杉醇诱导耐药细胞凋亡率,增强A549/T细胞中紫杉醇和Rh123的蓄积能力,同时,亦可明显抑制A549/T细胞中Ⅲ型β微管蛋白的表达水平。结论南强菌素可有效提高耐药细胞对紫杉醇的敏感性,逆转A549/T细胞对紫杉醇的耐药作用,其逆转机制可能与南强菌素抑制耐药肿瘤细胞膜上耐药蛋白P-糖蛋白的外泵转运功能和干扰Ⅲ型β微管蛋白的表达水平有关。 Objective To investigate the effect and mechanism of deacetyl-mycoepoxydiene (DM) on reversing resist- ance to taxol in tumor cells. Methods MTT colorimetric assay was employed to evaluate the cytotoxicity of DM to sensitive tumor cells A549 and drug resistant cells A549/T. The influence of DM on cellular taxol sensitivity was analyzed as well. The reversal fold was approximated by MTT, and the apoptotic percentage was estimated in AnnexinV method. The accumulation of Rh123 in drug-resistance cells was observed by flow cell cytometry (FCM). Additionally, the content of taxol and the expression of III-β-tubulin protein were respectively quantified by high performance liquid chromatography (HPLC) and Western blotting. Results This study demonstrated that DM enhanced the cellular taxol sensitivity and thus increased the apoptotic percentage of taxol-resistant tumor ceils. The content of taxol and Rh123 was greatly increased in DM-treated A549/T cells. Moreover, Western blotting results showed that DM inhibited the expression of III-β-tubulin protein in A549/T cells. Conclusion DM can effectively reverse the multidrug resistance and increase the drug sensitivity of tumor cells, which may function by interfering the expression of III-βtubulin protien and/or inhibiting the drug-resistant P-glyco-protein-mediated efflux pump on the cell membrane.
出处 《山东大学学报(医学版)》 CAS 北大核心 2013年第4期21-25,共5页 Journal of Shandong University:Health Sciences
基金 国家自然科学基金面上项目(81072569) 国家自然科学基金青年项目(31000368) 山东省自然科学基金面上项目(ZR2010HM088)
关键词 南强菌素 紫杉醇 肿瘤细胞 多药耐药性 A549 Deacetyl-mycoepoxydiene Taxol Tumor cells Multidrug resistance A549
  • 相关文献

参考文献15

  • 1Checchi P M, Nettles J H, Zhou J, et al. Microtubule-in- teracting drugs for cancer treatment E J ] Trends Pharma- col Sci, 2003, 24(7):361-365.
  • 2沈月毛,杨丽姗,黄耀坚,等.抗肿瘤化合物去乙酰真菌环氧乙酯及其制备方法[P].2008,专利号:ZL200610036892.6.
  • 3Prachya S, Wiyakrutta S, Sriubolmas N, et al. Cytotoxic mycoepoxydiene derivatives from an endophytic fungus Phomopsis sp. isolated from Hydnocarpus anthelminthicus [J]- Planta Med, 2007, 73(13):1418-1420.
  • 4戴明,罗荣城,钟华成,梁卫江,陈晓华,刘辉.紫杉醇耐药人肺腺癌细胞系的建立及生物学活性[J].实用医学杂志,2007,23(18):2826-2829. 被引量:5
  • 5Shi Y Q, Qu x J, Liao Y X, et al. Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resist- ance in adriamycin-resistant K562/A02 cells [J]. Europe- an Journal of Pharmacology, 2008, 584 (2) :66-71.
  • 6Martello L A, Verdier-Pinard P, Shen H J, et al. Elevat- ed levels of microtubule destabilizing factors in a Taxol-re- sistant/dependent A549 cell line with an alpha-tubulin mu- tation [ J ]. Cancer Res, 2003, 63 (6) : 1207-1213.
  • 7Jordan M A, Wilson L. Micrombules as a target for anti- cancer drugs [J]. Nat Rev Cancer, 2004, 4(4) :253-265.
  • 8Mozzetti S, Ferlini C, Concolino P, et al. Class III [3-tu- bulin overexpression is a prominent mechanism of paclita- xel resistance in ovarian cancer patients [ J ]. Clin Cancer Res, 2005, 11 ( 1 ) :298-305.
  • 9S6ve P, Dumontet C. Is class III [3-tubulin a predictive factor in patients receiving tubulin-binding agents? E J ]. Lancet Oncol, 2008, 9 (2) :168-175.
  • 10Lee K M, Cao D, Itami A, et al. Class III [3-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neo- plasia [J]. Histopathology, 2007, 51(4) :539-546.

二级参考文献20

  • 1张彩霞,林能明.吉西他滨药代动力学研究进展[J].肿瘤学杂志,2004,10(4):271-274. 被引量:10
  • 2张雪玲,糜漫天,李等松,韦娜,张乾勇,杨志祥.洛伐他汀对HL-60细胞bcl-2基因表达的影响[J].中国公共卫生,2004,20(6):658-659. 被引量:4
  • 3赵琦峰,章岳峰,杜杰.肺癌中MDR基因产物LRP、P-gp、GST-π、TopoⅡ的表达及临床意义[J].实用医学杂志,2005,21(23):2629-2632. 被引量:4
  • 4Jordan MA,Kamath K.How do microtubule-targeted drugs work? An overview[J].Curr Cancer Drug Targets,2007,7(8):730-742.
  • 5Sève P,Dumontet C.Chemoresistance in non-small cell lung cancer[J].Curr Med Chem Anticancer Agents,2005,5(1):73-88.
  • 6Yusuf RZ,Duan Z,Lamendola DE,et al.Paclitaxel resistance:molecular mechanisms and pharmacologic manipulation[J].Curr Cancer Drug Targets,2003,3(1):1-19.
  • 7Le Moguen K,Lincet H,Deslandes E,et al.Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10[J].Proteomics,2006,6(19):5183-5192.
  • 8González-Santiago L,Alfonso P,Suárez Y,et al.Proteomic analysis of the resistance to aplidin in human cancer cells[J].J Proteome Res,2007,6(4):1286-1294.
  • 9Besada V,Diaz M,Becker M,et al.Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance[J].Proteomics,2006,6(3):1038-1048.
  • 10Zhang JT,Liu Y.Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment[J].Cancer Treat Rev,2007,33(8):741-756.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部